Whitehawk Therapeutics Inc. (WHWK)
NASDAQ: WHWKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
WHWK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $181.16M
- EPS (TTM)
- -$1.10
- Dividend yield
- None
- 52-week range
- 2.10 – 5.50
- Day range
- 2.96 – 3.14
- Volume / Avg
- 451.08K / 348.68K
- Beta
- —
- Shares outstanding
- 59.01M
52-week range
WHWK stock today
On Nov 20, WHWK ended the session at $3.07, shedding $0.05 (1.60%), versus the S&P 500's 3.70% decline. Shares are 44.1% below their 52-week high of $5.50, set on May 14, 2026 and 46.2% above the 52-week low of $2.10, in the middle of the past year's range. WHWK is up 26.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 45.5%.
Whitehawk Therapeutics has posted a net loss over the last twelve months (EPS of -$1.10), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Whitehawk Therapeutics
Company profileWhitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. David J. Lennon Ph.D.
- Headquarters
- Morristown, NJ
- Employees
- 37
- Website
- ir.whitehawktx.com
Financial highlights
Full financialsIn fiscal 2025, Whitehawk Therapeutics generated $7.1 million in revenue, down 72.5% from fiscal 2024, its first annual decline since 2019. Whitehawk Therapeutics reported a net loss of $20.6 million, compared with a loss of $63.7 million a year earlier. Gross margin was 89.4% (up from 88.4%) and operating margin -1601.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $7.14M | $25.98M | $24.35M | $15.22M | $14.00M |
| Growth | -72.50% | +6.69% | +60.06% | +8.69% | 0.00% |
| Net income | $-20.60M | $-63.69M | $-65.77M | $-60.51M | $-110.09M |
| EPS (diluted) | $-0.33 | $-2.36 | $-2.44 | $-2.69 | $-12.41 |
Analyst forecast
ForecastConsensus (9 analysts)
buy
Avg. price target
$7.71+151.14%
- Strong buy 1
- Buy 5
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.23 vs $-0.24
- Surprise
- +4.17%
Whitehawk Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RNACCartesian Therapeutics Inc. | 6.14 | +4.24% | $187.29M | vs WHWK |
| SLGLSol-Gel Technologies Ltd. | 55.17 | +2.02% | $180.63M | vs WHWK |
| ADCTADC Therapeutics SA | 1.28 | -1.54% | $180.05M | vs WHWK |
| NATRNature's Sunshine Products Inc. | 10.18 | +0.10% | $176.41M | vs WHWK |
| VOGXVogenx Inc | 11.87 | -7.30% | $176.33M | vs WHWK |
| ANTXAN2 Therapeutics Inc. | 5.08 | -2.68% | $192.75M | vs WHWK |
| ACIUAC Immune SA | 1.95 | -8.45% | $193.88M | vs WHWK |
| SIGASIGA Technologies Inc. | 2.40 | -9.43% | $172.45M | vs WHWK |
Indexes, lists and sector
Whitehawk Therapeutics stock FAQ
What is Whitehawk Therapeutics's stock price today?
WHWK last traded at $3.07 as of Nov 20, 4:00 PM EST, down 1.60% on the day. Prices are delayed at least 15 minutes.
Does Whitehawk Therapeutics pay a dividend?
No. Whitehawk Therapeutics does not currently pay a regular cash dividend.
Who is Whitehawk Therapeutics's CEO?
Dr. David J. Lennon Ph.D. is the chief executive officer of Whitehawk Therapeutics Inc., which has about 37 employees.
Has WHWK ever split its stock?
Yes. The most recent WHWK stock split was a 1-for-15 split on Aug 27, 2021.
What is the WHWK 52-week high?
The 52-week high for WHWK is $5.50 and the 52-week low is $2.10. The stock is currently 44.1% below its high.